PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that data from its Phase 3 pivotal studies of investigational drug crisaborole topical ointment, 2% will be presented at the 74th Annual Meeting of the American Academy of Dermatology in Washington, D.C. “Crisaborole Topical Ointment, 2%: a Novel, Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor: Results from Two Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis” was accepted as a late-breaking abstract for oral presentation on Saturday, March 5, 2016 at 10:12 a.m., in Room 146C.
